February 7, 2014 – OncoMed Pharmaceuticals, Inc. [OMED], a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will visit the NASDAQ MarketSite in Times Square. In honor of the occasion, Paul J. Hastings, Chairman & CEO, will ring the Closing Bell.
The University of Rhode Island Doctor of Pharmacy program is accredited by the Accreditation Council for Pharmacy Education.
20 North Clark Street
Chicago, IL 60602-5109
Paul Hasting ’84, CEO of OncoMed Pharmaceuticals, Inc. to ring the Closing NASDAQ Bell Today
Copyright © 2014 University of Rhode Island.